• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BRAF抑制联合肿瘤治疗电场用于治疗多灶性进展性多形性黄色星形细胞瘤。

BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.

作者信息

Lukas Rimas V, Merrell Ryan T

机构信息

Department of Neurology, Lurie Cancer Center, Northwestern University, Chicago, IL 60611, USA.

Department of Neurology, Northshore University HealthSystem, Evanston, IL 60201, USA.

出版信息

CNS Oncol. 2018 Apr;7(2):CNS10. doi: 10.2217/cns-2017-0032. Epub 2018 Apr 30.

DOI:10.2217/cns-2017-0032
PMID:29708404
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5977279/
Abstract

Pleomorphic xanthoastrocytomas can be very resistant to treatment if they progress after standard therapy with surgery and radiation. We present the case of a patient with a multiply recurrent pleomorphic xanthoastrocytoma which demonstrated a sustained partial response to a combination regimen of the BRAF inhibitor vemurafenib and tumor treating fields. The regimen proved tolerable and efficacious in this case.

摘要

多形性黄色星形细胞瘤如果在接受手术和放疗的标准治疗后进展，可能对治疗具有很强的抗性。我们报告了一例多形性黄色星形细胞瘤多次复发的患者，该患者对BRAF抑制剂维莫非尼和肿瘤电场治疗的联合方案表现出持续的部分缓解。该方案在该病例中证明是可耐受且有效的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da6c/5977279/945f88692c1f/cns-07-10-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da6c/5977279/945f88692c1f/cns-07-10-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da6c/5977279/945f88692c1f/cns-07-10-g1.jpg

相似文献

1
BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.BRAF抑制联合肿瘤治疗电场用于治疗多灶性进展性多形性黄色星形细胞瘤。
CNS Oncol. 2018 Apr;7(2):CNS10. doi: 10.2217/cns-2017-0032. Epub 2018 Apr 30.
2
Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.BRAF抑制剂用于复发性多形性黄色星形细胞瘤的挽救治疗：一项回顾性病例系列研究
J Neurooncol. 2013 Sep;114(2):237-40. doi: 10.1007/s11060-013-1176-5. Epub 2013 Jun 12.
3
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.达拉非尼用于BRAFV600突变的间变性多形性黄色星形细胞瘤
CNS Oncol. 2017 Jan;6(1):5-9. doi: 10.2217/cns-2016-0031. Epub 2016 Oct 26.
4
Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.维莫非尼单药成功治疗进展性BRAF V600E突变的间变性多形性黄色星形细胞瘤
J Clin Oncol. 2016 Apr 1;34(10):e87-9. doi: 10.1200/JCO.2013.51.1766. Epub 2014 Aug 4.
5
Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.BRAF V600E 突变型促纤维增生性婴儿型星形细胞瘤患儿再次使用 vemurafenib 治疗后的反应。
Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26893. Epub 2017 Dec 12.
6
Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.一例间变性多形性黄色星形细胞瘤患者在BRAF抑制治疗进展后对BRAF/MEK抑制的反应
Neurologist. 2018 Sep;23(5):163-166. doi: 10.1097/NRL.0000000000000194.
7
[Anaplastic pleomorphic xanthoastrocytoma - single-center analysis of 42 patients].[间变性多形性黄色星形细胞瘤——42例患者的单中心分析]
Zh Vopr Neirokhir Im N N Burdenko. 2022;86(2):45-54. doi: 10.17116/neiro20228602145.
8
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.贝伐珠单抗、伊立替康、替莫唑胺、酪氨酸激酶抑制和 MEK 抑制对多形性黄色星形细胞瘤有效，与 V600E 状态无关。
J Neurooncol. 2018 Nov;140(2):261-268. doi: 10.1007/s11060-018-2975-5. Epub 2018 Aug 17.
9
Long-term Efficacy of Single-agent Vemurafenib for Pleomorphic Xanthoastrocytoma.单药维莫非尼治疗多形性黄色星形细胞瘤的长期疗效
J Pediatr Hematol Oncol. 2020 Mar;42(2):152-155. doi: 10.1097/MPH.0000000000001395.
10
Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.一名播散性间变性多形性黄色星形细胞瘤患者对靶向治疗的持续反应
J Pediatr Hematol Oncol. 2018 Aug;40(6):478-482. doi: 10.1097/MPH.0000000000001032.

引用本文的文献

1
Clinical outcomes for pleomorphic xanthoastrocytoma patients.多形性黄色星形细胞瘤患者的临床结局。
Neurooncol Pract. 2024 Aug 10;12(1):45-50. doi: 10.1093/nop/npae074. eCollection 2025 Feb.
2
Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging.基于 MRI 形态学特征和弥散加权成像的非侵入性预测多形性黄色星形细胞瘤的 BRAF V600E 突变状态。
BMC Cancer. 2024 Aug 19;24(1):1022. doi: 10.1186/s12885-024-12713-9.
3
Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a review of the literature.

本文引用的文献

1
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.肿瘤治疗电场联合维持性替莫唑胺与单纯维持性替莫唑胺对胶质母细胞瘤患者生存的影响：一项随机临床试验
JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718.
2
Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.世界卫生组织 2016 年脑肿瘤分类、分子标志物和临床结局更新对多形性黄色星形细胞瘤的影响。
J Neurooncol. 2018 Jan;136(2):343-350. doi: 10.1007/s11060-017-2658-7. Epub 2017 Nov 16.
3
多形性黄色星形细胞瘤：单机构回顾性分析及文献复习。
Radiol Med. 2022 Oct;127(10):1134-1141. doi: 10.1007/s11547-022-01531-3. Epub 2022 Aug 11.
4
A clinicopathologic study of malignancy in VCP-associated multisystem proteinopathy.VCP 相关多系统蛋白病中恶性肿瘤的临床病理研究。
Orphanet J Rare Dis. 2022 Jul 15;17(1):272. doi: 10.1186/s13023-022-02403-9.
5
The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.多形性黄色星形细胞瘤的演变：从起源到分子改变和模拟。
Lab Invest. 2022 Jul;102(7):670-681. doi: 10.1038/s41374-021-00708-0. Epub 2022 Jan 14.
6
Pleomorphic xanthoastrocytoma: a brief review.多形性黄色星形细胞瘤：简要综述
CNS Oncol. 2019 Nov 1;8(3):CNS39. doi: 10.2217/cns-2019-0009. Epub 2019 Sep 19.
Tumor Treating Fields in Neuro-Oncological Practice.
神经肿瘤学实践中的肿瘤治疗电场
Curr Oncol Rep. 2017 Aug;19(8):53. doi: 10.1007/s11912-017-0611-8.
4
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.达拉非尼用于BRAFV600突变的间变性多形性黄色星形细胞瘤
CNS Oncol. 2017 Jan;6(1):5-9. doi: 10.2217/cns-2016-0031. Epub 2016 Oct 26.
5
Tumor treating fields: a novel treatment modality and its use in brain tumors.肿瘤治疗电场：一种新型治疗方式及其在脑肿瘤中的应用。
Neuro Oncol. 2016 Oct;18(10):1338-49. doi: 10.1093/neuonc/now182.
6
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.替莫唑胺联合肿瘤电场治疗与替莫唑胺单药治疗胶质母细胞瘤的维持治疗：一项随机临床试验。
JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.
7
Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib.具有间变特征的原发性脑膜多形性黄色星形细胞瘤：2例报告，其中1例存在BRAF（V600E）突变并对BRAF抑制剂达拉非尼有临床反应
J Neuropathol Exp Neurol. 2015 Oct;74(10):960-9. doi: 10.1097/NEN.0000000000000240.
8
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.维莫非尼用于治疗伴有BRAF V600突变的多种非黑色素瘤癌症。
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
9
Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.多形性黄色星形细胞瘤：自然病史及长期随访
Brain Pathol. 2015 Sep;25(5):575-86. doi: 10.1111/bpa.12217. Epub 2014 Dec 5.
10
Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.维莫非尼单药成功治疗进展性BRAF V600E突变的间变性多形性黄色星形细胞瘤
J Clin Oncol. 2016 Apr 1;34(10):e87-9. doi: 10.1200/JCO.2013.51.1766. Epub 2014 Aug 4.